Table 1. Summary of Patient Characteristics.
| Characteristic | Discovery (n = 173) | Replication (n = 42) | Combined cohort P value (n = 215) | ||||
|---|---|---|---|---|---|---|---|
| No. (%) | P value | No. (%) | P value | ||||
| Cases (n = 51) | Controls (n = 122) | Cases (n = 20) | Controls (n = 22) | ||||
| Age at time of treatment, median (IQR), y | 56 (44-61) | 51 (43-60) | .003 | 50 (42-54) | 46 (41-54) | .89 | .01 |
| Cumulative dose, median (range), mg/m2 | 434.2 (300-550) | 422.7 (400-600) | .002 | 420.5 (420-435) | 421.7 (420-450) | .11 | .001 |
| Hormonal therapya | |||||||
| AIs | 20 (39.2) | 43 (35.2) | .46 | 10 (50.0) | 5 (22.7) | .11 | .18 |
| Steroidal AIs | 1 (2.0) | 8 (6.6) | .45 | 2 (10.0) | 1 (4.5) | .60 | .75 |
Abbreviations: AIs, aromatase inhibitors; IQR, interquartile range.
a
Data available for only 186 patients, with 144 in the discovery phase.